Pyrls is a drug summaries resource for learning and managing therapy points and clinical pearls about more than 500 leading medicines.
Pyrls has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in March 2022.
Pyrls's investors include Y Combinator.
Pyrls is headquartered in Minneapolis, United States.
Pyrls is a drug summaries resource for learning and managing therapy points and clinical pearls about more than 500 leading medicines.
Pyrls is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pyrls — Funding & Investors." VCBacked, March 9, 2022, https://www.vcbacked.co/company/pyrls. Accessed August 15, 2026.
VCBacked. (2022). Pyrls — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/pyrls
{{cite web |title=Pyrls — Funding & Investors |url=https://www.vcbacked.co/company/pyrls |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated